The Pulmonary Fibrosis Foundation (PFF) has announced its keynote speakers for the upcoming PFF Summit 2017, a biennial meeting set for Nov. 9-11 in Nashville, Tennessee. During the event, physicians and researchers will present their most current work on pulmonary fibrosis (PF), stem cell therapies, medical tourism and advances in…
News
A Phase 2/3 clinical trial of PBI-4050, a potential new therapy for idiopathic pulmonary fibrosis (IPF), has been approved by the U.S. Food and Drug Administration (FDA), according to Prometic Life Sciences. The FDA has granted the drug candidate investigational new drug (IND) status, which facilitates clinical research. The Phase 2/3…
Clinical trial results of Patara Pharma’s inhaled therapy candidate PA101 for chronic cough caused by idiopathic pulmonary fibrosis (IPF) indicate the medication reduces cough in a disease-specific manner. The findings, published in the journal The Lancet Respiratory Medicine, were derived from a Phase 2 trial (NCT02412020) of…
The American Lung Association and Three Lakes Partners are teaming up to raise awareness about idiopathic pulmonary fibrosis (IPF) during Pulmonary Fibrosis Awareness Month in September. The announcement was made at the European Respiratory Society’s International Congress (ERS 2017) in Milan, Italy. “IPF is a challenging and unpredictable disease, and…
An evaluation of 52 gene profiles in blood samples can help predict the clinical outcome of patients with idiopathic pulmonary fibrosis (IPF), finds a study published in The Lancet Respiratory Medicine. If confirmed in future studies, this gene expression profile evaluation could improve currently used outcome measures, as well as IPF patient…
A post-hoc analysis of data from Phase 3 studies shows that Esbriet (pirfenidone) can significantly reduce the incidence of disease progression events in people with idiopathic pulmonary fibrosis (IPF) — including respiratory-related hospitalizations, decline in lung function and physical capacity, and the risk of death — compared to placebo. These results…
PMD Healthcare is among the companies and groups marking Pulmonary Fibrosis Month, and supporting efforts to raise awareness of pulmonary fibrosis (PF) and improve the care of people with this disease. PF Month, which runs through September, stems from an initiative created by the Pulmonary Fibrosis Foundation (PFF) to  educate the…
Boehringer Ingelheim has joined idiopathic pulmonary fibrosis experts and patient advocacy groups to raise awareness of the early signs and symptoms of the disease. To help mark IPF World Week from Sept. 16 to 24, the company has created several educational tools to help doctors identify the characteristics of IPF…
The latest Phase 2 trial results of the investigative therapy Pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) further demonstrated the drug’s therapeutic potential to reduce fibrosis progression and ameliorate IPF clinical manifestations, with no reported adverse toxicity. So concludes an oral presentation, “RAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical…
An inhaled version of miRagen Therapeutics‘ potential fibrosis therapy MRG-201 rendered genes involved in scarring nearly inactive in a rat model of lung fibrosis, the company reported. The preclinical-trial study also showed that most of the compound reached the animals’ lungs. The fact that little of it was found in other tissue…
